Novo Nordisk A/S: Operating profit increased by 18% in the first quarter of 2012 (27 April 2012)

Lars Rebien Sørensen, president and CEO: “We are satisfied with the solid sales growth duringthe first quarter of 2012 – still driven by the modern insulins NovoRapid® and Levemir® as wellas our once-daily human GLP-1 Victoza®. Furthermore, the regulatory reviews for Tresiba® andRyzodeg®, our new generation of insulins, continue to progress well in the major markets.”

Sales growth of 13% driven by Victoza®, NovoRapid® and Levemir®

Sales increased by 13% to 17.8 billion in Danish kroner and by 10% in local currencies.

 

Sales of modern insulins increased by 17% (14% in local currencies).

Sales of Victoza® increased by 81% (76% in local currencies).

Sales in North America increased by 21% (17% in local currencies).

Sales in International Operations increased by 24% (24% in local currencies).

 

Gross margin improved by 0.7 percentage points in Danish kroner to 80.8% in the first quarter of 2012, reflecting a favourable price and product mix development.

Reported operating profit increased by 18% to DKK 6,385 million. Measured in local currencies, operating profit increased by approximately 13%.

Net profit increased by 15% to DKK 4,664 million. Earnings per share (diluted) increased by 18% to DKK 8.32.

The regulatory reviews of the new ultra-long-acting insulins Degludec and DegludecPlus continue to progress in the major markets. The intended global brand name for Degludec is Tresiba® and the intended global brand name for DegludecPlus is Ryzodeg®.

Novo Nordisk has initiated a phase 3a programme for the long-acting recombinant factor VIII compound N8-GP for the treatment of haemophilia A.

For 2012, sales growth measured in local currencies is now expected to be 8-11% (previously 7-11%), and operating profit growth measured in local currencies is now expected to be at least 10% (previously around 10%).

Lars Rebien Sørensen, president and CEO: "We are satisfied with the solid sales growth during the first quarter of 2012 - still driven by the modern insulins NovoRapid® and Levemir® as well as our once-daily human GLP-1 Victoza®. Furthermore, the regulatory reviews for Tresiba® and Ryzodeg®, our new generation of insulins, continue to progress well in the major markets."

Further information:

Media:

Investors:

   

Mike Rulis

Klaus Bülow Davidsen

Tel: (+45) 4442 3573

Tel: (+45) 4442 3176

mike@novonordisk.com

klda@novonordisk.com

   
 

Lars Borup Jacobsen

 

Tel: (+45) 3075 3479

 

lbpj@novonordisk.com

   
 

Frank Daniel Mersebach

 

Tel: (+45) 4442 0604

 

fdni@novonordisk.com

   

In North America:

In North America

Ken Inchausti

Jannick Lindegaard

Tel: (+1) 609 786 8316

Tel: (+1) 609 786 4575

kiau@novonordisk.com

jlis@novonordisk.com

 

Read the full announcement in PDF format

Posted: April 2012


View comments

Hide
(web2)